Navigation Links
Biotech Hall of Fame Inductees Announced

Outstanding Companies, Individuals, and Scientific Achievements are Honored

at the 20th Biotech Meeting, Laguna Niguel

LAGUNA NIGUEL, Calif., Oct. 8 /PRNewswire/ -- At the 20th Annual Biotech Meeting at Laguna Niguel, a biotech CEO-only conference hosted by Burrill & Company and Kleiner Perkins Caufield & Byers, inductees into the Biotech Hall of Fame were announced at an Awards Dinner held here Sunday evening.

For twenty years, the CEOs of the biotech industry have recognized the outstanding achievements of the past year, heralding colleagues, companies behind the scientific breakthroughs and business success. To commemorate the 20th year of the Biotech meeting CEO's voted on a slate of nominees for three categories: Leading Company, Special Recognition for an Individual, and Scientific Achievement. The nominees were selected by G. Steven Burrill, CEO, Burrill & Company, Brook Byers, Senior Partner at Kleiner, Perkins, Caufield & Byers and a special advisory committee. Unlike the previous award processes, the nominations were not made on the basis of the past year's performance but their total contribution to the biotechnology industry. The inductees are:

Leading Company

Celgene Inc.

Lead products include THALOMID for the treatment and suppression of

cutaneous manifestations of erythema nodosum leprosum, an inflammatory

complication of leprosy. The company's products also include REVLIMID

for the treatment of patients with transfusion-dependent anemia.

Current market cap is $28 billion.

Idexx Pharmaceuticals

A leader in innovative products and services for a variety of

veterinary, food and water applications. Their companion animal and

equine businesses combine biotechnology with medical devices and

information technology to support veterinarians.

Illumina Inc.

Developer, manufacturer and marketer of next-generation life-science

tools and integrated systems for the large-scale analysis of genetic

variation and biological function.

Onyx Pharmaceuticals

Developer of innovative small molecule cancer treatments based on a

molecular understanding of cancer. Onyx's lead product is Nexavar(R)

(sorafenib) tablets, an oral multiple kinase inhibitor that targets

proteins involved in both tumor cell proliferation and angiogenesis

(the formation of new blood vessels to support cancer cell growth).

Vertex Pharmaceuticals

The Company is leading the development of the HCV protease inhibitor,

telaprevir (VX-950), and in 2007 is conducting a broad Phase 2

clinical program of this drug candidate. Vertex is also focused on the

development of VX-702, a p38 MAP kinase inhibitor for the treatment of

rheumatoid arthritis, and VX-770, an investigational drug candidate

for cystic fibrosis.

Special Recognition for an Individual

Jim Greenwood, President and CEO, Biotechnology Industry Organization


BIO represents more than 1,100 biotechnology companies, academic

institutions, state biotechnology centers and related organizations in

all 50 U.S. states and 31 other nations.

Susan D. Desmond-Hellmann, President, Product Development, Genentech


Genentech is one of the biotech industry's leading companies and Dr.

Desmond-Hellmann has overseen the development of several promising

cancer drugs and the final testing phase of others.

John C. Martin, President and CEO, Gilead Sciences Inc.

Dr. Martin joined Gilead Sciences in 1990 and has served as President

and Chief Executive Officer since 1996. The company has expanded

rapidly over the past two decades, with annual revenues now exceeding

$3 billion

Ed Penhoet, Co-Founder of Chiron Corp.

He was president and CEO of the prominent biotechnology company until

May 1998. He has held leadership positions in the biotechnology

industry and in academia, and is currently vice chair of the

state-appointed board overseeing California's $3 billion stem cell

research initiative.

Hollings C. Renton, Chairman, President and CEO, Onyx Pharmaceuticals

He has served as President, Chief Executive Officer and Director of

the company since 1993. Prior to joining Onyx, Mr. Renton was the

President and Chief Operating Officer of Chiron Corporation.

Scientific Achievement

Harold E. Varmus and J. Michael Bishop

Co-recipients of the 1989 Nobel Prize in Physiology or Medicine for

their discovery of the cellular origins of retroviral oncogenes. They

directed the research that led to the discovery of proto-oncogenes --

normal genes that can be converted to cancer genes by genetic damage.

This work eventually led to the recognition that all cancer probably

arises from damage to normal genes, and provided new strategies for

the detection and treatment of cancer.

Francis Collins

Director of the National Human Genome Research Institute (NHGRI) at

the National Institutes of Health (NIH). He led the successful effort

to complete Human Genome Project (HGP), a complex multidisciplinary

scientific enterprise directed at mapping and sequencing all the human

DNA, and determining aspects of its function.

Napoleone Ferrera

Dr. Ferrara and his team of scientists at Genentech Inc. made a

groundbreaking discovery that added greatly to our understanding and

treatment of cancer. It was the identification and cloning of a gene

termed vascular endothelial growth factor, or VEGF, which produces a

protein that plays a critical role in angiogenesis.

Andrew Z. Fire and Craig C. Mello

Co-recipients of the 2006 Nobel Prize in Physiology or Medicine for

their discovery of RNA interference -- gene silencing by

double-stranded RNA. RNA interference occurs in plants, animals, and

humans. It is of great importance for the regulation of gene

expression, participates in defense against viral infections, and

keeps jumping genes under control. RNA interference is widely used in

basic science as a method to study the function of genes and it may

lead to novel therapies.

Robert Langer

In 1999 Forbes magazine named Prof. Langer, Department of Chemical

Engineering, Massachusetts Institute of Technology, as one of the 25

most important individuals in biotechnology in the world. His work is

at the interface of biotechnology and materials science. A major focus

is the study and development of polymers to deliver drugs,

particularly genetically engineered proteins, DNA and RNAi,

continuously at controlled rates for prolonged periods of time.

"There is no greater recognition than that of one's peers," commented G. Steven Burrill, CEO of Burrill & Company, "and we are delighted to recognize these outstanding inductees to the Biotech Hall of Fame."

The Biotech Meeting at Laguna Niguel is the premier industry conference exclusively for CEOs of biotechnology companies. The Biotech Meeting (now in its 20th year) is held annually at The Ritz-Carlton Hotel in Laguna Niguel (Southern California). It is running October 8-9, 2007 and over 250 leading biotech CEOs have gathered to share management ideas, set an agenda for the industry and network with each other.

About Kleiner Perkins Caufield & Byers

Since its founding in 1972, Kleiner Perkins Caufield & Byers has backed entrepreneurs in 475 ventures, including AOL, Align,, Citrix, Compaq Computer, Electronic Arts, Genentech, Genomic Health, Google, IDEC Pharmaceuticals, Intuit, Juniper Networks, Netscape, Lotus, LSI Logic, Sun Microsystems, Symantec, Verisign, and Xilinx. More than 150 of the firm's portfolio companies have gone public. Many other ventures have achieved success through mergers and acquisitions. KPCB has broadly invested in both life sciences and information technology since inception in 1972. In the last seven years, KPCB has expanded its focus to include Greentech and pandemic preparedness. . KPCB has committed more than $200 million to 25 Greentech ventures over the past seven years, including Altra Biofuels, Amyris Biotechnologies, Ausra, Bloom Energy, Great Point Energy, Mascoma, Miasole, and Verdiem.

About Burrill & Company

Burrill & Company is a San Francisco-based global leader in life sciences with principal activities in Venture Capital, Merchant Banking and Media. The company's over 50-person scientific and business team, supported by its Advisory Boards, the strategic and financial network of its limited partners, and the close relationships developed with numerous life science companies and managements, provide Burrill with unparalleled access and insight. The Burrill Life Sciences Media Group, a joint venture of Burrill & Company and Nielsen Business Media, produces worldwide life sciences conferences, and leading publications including an annual book on the "State of the Industry, the 21st Edition is Biotech 2007: Life Sciences-A Global Transformation; a series of bio-intelligence reports, The Journal of Life Sciences, in association with the California Healthcare Institute, and the Burrill Biotechnology Intelligence Report, which tracks the progress of the industry through its Burrill Biotech Indices and monthly financial analysis of the deals, partnerships and M&As.

SOURCE Burrill & Company
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
(Date:11/24/2015)... AVIV, Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: ... held on December 29, 2015 at 11:00 a.m. Israel ... Co., Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... election of Eric Paneth and Izhak Tamir to ... and Rami Skaliter as external directors; , approval of an amendment ...
(Date:11/24/2015)... SAN FRANCISCO , Nov. 24, 2015 /PRNewswire/ ... today announced that Emily Leproust, Ph.D., Twist Bioscience ... Piper Jaffray Healthcare Conference on December 1, 2015 ... Palace Hotel in New York City. ... . Twist Bioscience is on ...
(Date:11/24/2015)... Switzerland (PRWEB) , ... November 24, 2015 , ... InSphero ... organotypic 3D cell culture models, has promoted Melanie Aregger to serve as Chief Operating ... Ms. Aregger served on the management team and was promoted to Head ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. ... that Mr. Pierre Laurin , President and Chief Executive ... the upcoming Piper Jaffray 27 th Annual Healthcare Conference ... December 1-2, 2015. st , at 8.50am ... meetings throughout the day. The presentation will be available live ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th until 19 ... from 17 th until 19 th November 2015. ... invented the first combined scanner in the world which scans ... now two different scanners were required: one for passports and ... the same surface. This innovation is an ideal solution for ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
Breaking Biology News(10 mins):